INOFEA AG

Their core work

INOFEA AG is a Swiss biotechnology SME specializing in industrial enzyme discovery, engineering, and manufacturing — covering the full value chain from identifying promising enzymes in extreme environments to delivering scalable production processes. Their core work involves mining genomic and metagenomic data to find novel biocatalysts, then engineering those enzymes to meet industrial performance requirements. They apply these capabilities to replace harsh chemicals in consumer products: detergents, textiles, and cosmetics. More recently, they have added machine learning and big biodata approaches to accelerate enzyme discovery at scale.

What they specialise in

How they've shifted over time

In their first H2020 project (INMARE, 2015–2019), INOFEA focused on the upstream end: discovering enzymes from marine extremophiles using genomics and metagenomics, with biocatalysis and bioactive compounds as the primary outputs. By their second project (FuturEnzyme, 2021–2025), the focus shifted decisively downstream: enzyme engineering, enzyme manufacturing, and market-ready applications in detergents, textiles, and cosmetics, augmented by machine learning for large-scale data mining. The trend is a progression from pure discovery toward a complete commercialization pipeline, with circular economy principles now framing the work.

INOFEA is building toward a full-stack industrial biotechnology capability — discovery through manufacturing — and is positioning itself as a technology provider for sustainable consumer goods industries seeking to replace chemical processes with enzymatic ones.

How they like to work

INOFEA participates exclusively as a consortium partner rather than a project leader, suggesting they contribute specialist expertise rather than drive project strategy. Their presence in two large consortia totaling 32 unique partners across 14 countries points to comfort operating inside complex, multi-partner European research projects. This profile — specialist contributor in large consortia — means they are likely a focused technology node rather than a generalist coordinator, which makes them a lower-friction partner to bring into a consortium where a specific enzymatic capability is needed.

INOFEA has built connections with 32 unique consortium partners across 14 countries through just two projects, indicating they join large, geographically diverse European consortia. No single-country or bilateral focus is evident — their network is broadly European in character.

What sets them apart

INOFEA occupies a rare niche as a Swiss industrial biotechnology SME that connects marine extremophile science to consumer product manufacturing — a bridge very few small companies can credibly offer. Their combination of metagenomics-based discovery and engineering-to-manufacturing know-how means they can contribute at multiple stages of an enzyme development project, not just one. As a Swiss company, they also bring access to a research and industry network outside the EU proper, which can be valuable for consortia needing non-EU industrial partners.

Highlights from their portfolio

• FuturEnzyme
  Their best-funded project (EUR 390,000 EC contribution) and most commercially oriented, targeting low-cost enzyme production for greener detergents, bio-processed textiles, and cosmetics — a direct line from research to market.
• INMARE
  Established INOFEA's foundational expertise in marine extremophile enzyme mining and metagenomic screening, placing them in the Blue Growth sector at a time when marine biotech was gaining significant EU research attention.